Abstract:B-Raf is a member of the RAF family of serine/threonine kinases: it mediates cell, division, differentiation, and apoptosis signals through the RAS-RAF-MAPK pathway. Thus B-Raf is of keen interest in cancer therapy, such as melanoma. In this study, we propose the first Combination approach to integrate the pharmacophore (PhModel), CoMFA, and CoMSIA models for B-Raf, and this approach could be used for screening and optimizing potential B-Raf inhibitors in silico. Ten PhModels were generated based on the HypoGen BEST algorithm with the flexible fit method and diverse inhibitor structures. Each PhModel was designated to the alignment rule and screening interface for CoMFA and CoMSIA models. Therefore, CoMFA and CoMSIA models could align and recognize diverse inhibitor structures. We used two quality validation methods to test the predication accuracy of these combination models In the previously proposed combination approaches, they have a common factor in that the number of training set inhibitors is greater than that of testing set inhibitors. In our study, the 189 known diverse series B-Raf inhibitors, which are 7-fold the number of training set inhibitors, were used as a testing set in the partial least-squares validation. The best validation results were made by the CoMFA09 and CoMSIA09 models based on the Hypo09 alignment model. The predictive r(pred)(2) values of 0.56 and 0.56 were derived from the CoMFA09 and CoMSIA09 models, respectively. The CoMFA09 and CoMSIA09 models also had a satisfied predication accuracy of 77.78% and 80%, and the goodness of hit test score of 0.675 and 0.699, respectively. These results indicate that our combination approach could effectively identify diverse B-Raf inhibitors and predict the activity.

Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization

Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase with Potent Antimelanoma Activity.

Identification of Novel B-RafV600E Inhibitors Employing FBDD Strategy

Design of potent B-Raf V600E inhibitors by multiple copy simulation search strategy.

Design, Synthesis, and Biological Evaluation of New B-RafV600E Kinase Inhibitors

Recent Advances in the Research and Development of B-Raf Inhibitors

In Silico Identification of Novel Kinase Inhibitors by Targeting B-Rafv660e from Natural Products Database

Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold As Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies

Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf(V600E) inhibitors.

Identification and Biological Evaluation of Novel Type II B-Raf V600E Inhibitors.

Studies on [5,6]-Fused Bicyclic Scaffolds Derivatives As Potent Dual B-RafV600E/KDR Inhibitors Using Docking and 3D-QSAR Approaches.

Design, Synthesis, Biological Evaluation and Molecular Modeling of Novel 1H-Pyrazolo[3,4-d]pyrimidine Derivatives As BRAF(V600E) and VEGFR-2 Dual Inhibitors

Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the Dfg-In over the Dfg-Out Conformation of the B-Raf Kinase V600e Mutant in Colorectal Cancer

Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib.

N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors.

Design, Virtual Screening, Molecular Docking, ADME and Cytotoxicity Studies of 1,3,5-Triazine Containing Heterocyclic Scaffolds as Selective BRAF Monomeric, Homo and Heterodimeric Inhibitors

Virtual Screening of B-Raf Kinase Inhibitors: A Combination of Pharmacophore Modelling, Molecular Docking, 3D-QSAR Model and Binding Free Energy Calculation Studies

Identification and Synthesis of N-(thiophen-2-yl) Benzamide Derivatives As BRAF(V600E) Inhibitors.

Non-oxime inhibitors of B-Raf(V600E) kinase

Development of Novel 3D-QSAR Combination Approach for Screening and Optimizing B-Raf Inhibitors in silico.

Molecular Dynamics Simulation, Free Energy Calculation and Structure-Based 3D-QSAR Studies of B-RAF Kinase Inhibitors.